Search academic texts

Information × Registration Number 0212U004401, 0111U001426 , R & D reports Title Mechanisms of chronic myeloid leukemia evolution as a result of interrelation between genetically disturbed substrate cells and certain regulatory mechanisms of the patient body popup.stage_title Head Maslyak Zvenyslava Volodymyrivna, Registration Date 09-02-2012 Organization State Institution Institute of Blood Pathology and Transfusion Medicine of National Academy of Medicfl Sciences of Ukraine popup.description2 The group of 49 patients with chronic phase CML was formed, further monitoring of disease course was planned for the patients of this group treated with tyrosin kinase inhibitors (TKI). First subgroup included 20 patients with first diagnosis of CML. The second subgroup comprised 14 patients pretreated with non-TKI agents. The third subgroup consisted of 15 patients who had not achieved or lost their hematological and cytogenetic response to imatinib and who required change of their treatment approach. Complete hematological response was detected in all patients in subgroup 1 and 2 after 6 months of treatment with IM; patients of the 3rd subgroup achieved CHR in less than half of the cases. Cytogenetic response was the most rapid in patients of the 2nd subgroup, pretreated with interferon alfa prior to imatinib, almost all of them achieved optimal response according to European LeukemiaNet (ELN) criteria. Patients with the first dagnosis of CML showed optimal response in more than half of the cases; response achieved in the rest of the subjects could be considered as suboptimal. For the patients of the third subgroup resistant to imatinib tests for BCR-ABL mutations were performed in order to reveal possible reasons for resistance. Mutations were found in 6 patients: Y253H and M351T mutation were revealed in 1 case each; 2 patients were detected with E255V/K and another 2 - with F359V mutation. Other 9 patients had no BCR/ABL mutations diagnosed. Detection or absence of mutations were taken into account for correction of further treatment tactics of the patients - either IM dose increase or change to the 2nd line TKI - nilotinib. In conclusion, as a result of stage 1 of this research, variatons in cytogenetic response achievement in first diagnosed patients without any deviations in kariotype were revealed; aditionally about half of the patints resistant to imatinib were found to have BCR/ABL mutation even though they had no signs of clonal evolution according to cytogenetic monitoring. The resuts obtained suggest expediency and necessity of studying other pathogenetic aspects of CML which is planned to be performed within the next stages of this research. Product Description popup.authors Бойко Ольга Ігорівна Виговська Ярослава Іллівна Городиська Тетяна Омелянівна Даниш Ольга Йосипівна Дзісь Іван Євгенович Дяків Галина Львівна Котлярчук Костянтин Богданович Лещук Остап Васильович Лозинський Ростислав Юрійович Лук'янова Анна Сергіївна Лукавецький Лесь Миронович Мазурок Анна Антонівна Мельник Марія Іллярівна Павлишин Анна Михайлівна Сімонова Мар'яна Іванівна Томашевська Наталія Яремівна popup.nrat_date 2020-04-02 Close